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a b s t r a c t 
Cancer immunotherapies rely on how interactions between cancer and immune system cells are consti- 
tuted. The more essential to the emergence of the dynamical behavior of cancer growth these interactions 
are, the more effectively they may be used as mechanisms for interventions. Mathematical modeling can 
help unearth such connections, and help explain how they shape the dynamics of cancer growth. Here, 
we explored whether there exist simple, consistent properties of cancer-immune system interaction (CISI) 
models that might be harnessed to devise effective immunotherapy approaches. We did this for a fam- 
ily of three related models of increasing complexity. To this end, we developed a base model of CISI, 
which captures some essential features of the more complex models built on it. We find that the base 
model and its derivates can plausibly reproduce biological behavior that is consistent with the notion of 
an immunological barrier . This behavior is also in accord with situations in which the suppressive effects 
exerted by cancer cells on immune cells dominate their proliferative effects. Under these circumstances, 
the model family may display a pattern of bistability , where two distinct, stable states (a cancer-free, and 
a full-grown cancer state) are possible. Increasing the effectiveness of immune-caused cancer cell killing 
may remove the basis for bistability, and abruptly tip the dynamics of the system into a cancer-free state. 
Additionally, in combination with the administration of immune effector cells, modifications in cancer 
cell killing may be harnessed for immunotherapy without the need for resolving the bistability. We use 
these ideas to test immunotherapeutic interventions in silico in a stochastic version of the base model. 
This bistability-reliant approach to cancer interventions might offer advantages over those that comprise 
gradual declines in cancer cell numbers. 
© 2020 The Authors. Published by Elsevier Ltd. 
This is an open access article under the CC BY license. ( http://creativecommons.org/licenses/by/4.0/ ) 
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0. Introduction 
Mathematical modeling of cancer-immune system interactions
CISI) can reveal the fundamental mechanisms that govern the dy-
amics of tumor growth ( Altrock et al., 2015; Eftimie et al., 2010 ),
nd represent and important tool to devise and test new forms
f immunotherapy in silico ( Talkington et al., 2018 ). The model-
ng relies on the appropriate integration of how cancer and im-∗ Corresponding authors at: Institute of Applied Simulation, Zurich University of 
pplied Sciences, Einsiedlerstrasse 31a, 8820 Wädenswil, Switzerland. 
E-mail address: victor.garcia_palencia@alumni.ethz.ch (V. Garcia). 
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ttps://doi.org/10.1016/j.jtbi.2020.110185 
022-5193/© 2020 The Authors. Published by Elsevier Ltd. This is an open access article uune cells affect one another ( De Boer et al., 1985; de Pillis
t al., 2005; Goldstein et al., 2004; Kronik et al., 2008; Kuznetsov
t al., 1994 ). Recent studies have uncovered a plethora of interac-
ions by which cancer cells affect immune cells, and vice versa
 Mellman et al., 2011; Eftimie et al., 2010 ). For instance, can-
er cells elicit immune responses by a variety of effector cells
 Parish, 2003; Smyth et al., 2001; Mellman et al., 2011 ). These
ffector cells, in particular white blood cells, natural killer cells
NKs) and cytotoxic T lymphocytes (CTLs) can lyse cancer cells
 Quesnel, 2008 ), inhibiting tumor growth or even eliminating mi-
roscopic tumors altogether — a process termed immunosurveil-
ance ( Burnet, 1957; 1967 ). However, cancers have also been shownnder the CC BY license. ( http://creativecommons.org/licenses/by/4.0/ ) 
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Fig. 1. Cancer-immune system interactions and effects of immunotherapy . A) Interactions governing the dynamics between cancer cells (T) and immune cells targeting 
the cancer cells —termed effector cells— (E). A complex web of interactions has been identified ( Mellman et al., 2011; Eftimie et al., 2010; Altrock et al., 2015 ), with both cell 
types capable to both stimulate and suppress each others’ growth. B) Immunotherapy acts by either increasing the killing rate of effector cells, for example by administrating 
new effector cells into the host ( adoptive T cell transfer ), or by impairing the escape mechanisms cancer cells adopt to avoid being cleared, for example by monoclonal antibody 
therapy . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a  
L  
t  
(  
a  
2  
A  
2  
t  
a
 
p  
m  
i  
w  
t  
e  
t  
a  
d  
s  
c  
t  
s  
t  
T  
t  
w  
s  
n  
R  
2  
o  
(  
S  
Tto be able to suppress the proliferation of effector cells, which
typically target cancer cells with specific biochemical signatures
( Kooi et al., 1996; Hamanishi et al., 2007 ). Cancer cells accrue mu-
tations that, by changing these signatures, enable them to par-
tially evade immune recognition ( Altrock et al., 2015; Parsa et al.,
2007; Hanahan and Weinberg, 2011 ). Furthermore, cancers may ac-
tively downregulate immune responses elicited against them ( Keir
et al., 2008; Mellor and Munn, 2004; Aggarwal and Pittenger,
20 05; Munn and Mellor, 20 04; Marigo et al., 20 08 ), for example
by recruiting the action of T regulatory cells ( Mellman et al., 2011;
Ohta et al., 2006; Facciabene et al., 2011 ), leading to immunosu-
pression . A summary of these interactions shows that all combi-
nations of stimulation and suppression on growth between cancer
and immune cells may act simultaneously (see Fig. 1 A). These in-
teractions direct the interplay between the cancer and the immune
system. Thus, their integration into mathematical models can re-
veal how immunotherapeutic approaches may be employed with
maximum efficiency. The main immunotherapy approaches today
work by impairing mechanisms that allow cancers to suppress im-
mune action or by the administration of effector cells to the host
( Dougan and Dranoff, 2009; Mellman et al., 2011 ) (see Fig. 1 B). 
Due to their importance for immunotherapy, mathematical
models of cancer-immune interactions have been the focus of in-
tense theoretical effort s over the last decade ( Altrock et al., 2015;
Eftimie et al., 2010 ). At the heart of this effort lies the task of
identifying what features of cancer-immune dynamics are most
effectively used to achieve immunotherapeutic success, i.e. can-
cer eradication. Following this tradition, we focus on determin-
istic, population based non-spatial models for analysis. We do
this for two reasons. First, their mathematical simplicity is bet-
ter suited to unambiguously reveal those model properties that
are crucial for the modification of a cancer’s state, since the num-
ber of factors influencing the dynamics is manageable and un-
derstandable ( Eftimie et al., 2010 ). Second, we can draw from
a broad body of theory about immune system pressures devel-
oped within cancer research ( Kuznetsov et al., 1994; Kuznetsovnd Knott, 20 01; d’Onofrio, 20 05; 20 08; Eftimie et al., 2011; 2010;
opez et al., 2014 ) as well as in virus dynamics, and in par-
icular, human immunodeficiency virus (HIV) dynamics research
 Nowak and May, 20 0 0; Wodarz, 20 07; De Boer, 20 07a; Althaus
nd De Boer, 2008; Conway and Perelson, 2014; Garcia and Regoes,
015; Graw and Regoes, 2009; Graw et al., 2011; Yates et al., 2007;
lthaus and De Boer, 2008; Elemans et al., 2014; Garcia et al.,
015; Regoes et al., 2007 ). To explore immunotherapeutic interven-
ions in silico , we use a stochastic version of one of the models
nalyzed. 
In this study, we have explored whether there exist consistent
roperties of cancer-interaction models that facilitate effective im-
unotherapy approaches. We investigated this question in a fam-
ly of three related models of increasing complexity. To this end,
e first developed a base model of cancer immune system interac-
ion that captures some essential features of more complex mod-
ls. The purpose of the model is to gain qualitative insights and
hen to serve as a guide for treatment therapies based on immune
ction. We analyzed under what parameter regimes the model pro-
uces biologically plausible behavior, and investigated how steady
tates are affected by changes in these parameters. We then suc-
essively extended the model to first include more complex fea-
ures of cancer-immune system interactions ( Conway and Perel-
on, 2014 ), such as saturating proliferative stimulation and exhaus-
ion and in a second step, to include the action of NKs and CTLs.
he common properties identified in these models were then used
o study how combinations of immunotherapeutic treatments may
ork together to achieve eradication. To this end, we implemented
tochastic simulations of the base model and analyzed how the dy-
amics are affected by adoptive T cell transfer ( Rosenberg, 1991;
osenberg et al., 2004; Dudley et al., 2002; Rosenberg et al.,
008 ), as well as by the disruption of immune evasion mechanisms
f the cancer through for example monoclonal antibody therapy
 Mellman et al., 2011 ; Brahmer, Drake, Wollner, Powderly, Picus,
harfman, Stankevich, Pons, Salay, McMiller, Gilson, Wang, Selby,
aube, Anders, Chen, Korman, Pardoll, Lowy, Topalian, 2010 ). 
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Table 1 
Standard parameter values for the base model. 
Parameter Description Value 
a maximum replication rate of cancer cells ( de Pillis et al., 2005 ) 0.514 day 
−1 
b inverse carrying capacity of tumor ( de Pillis et al., 2005 ) 1 . 02 · 10 −9 cells −1 
k killing efficacy of immune cells ( Ganusov et al., 2011; Wick et al., 2005 ) 10 −4 − 10 cells −1 day −1 
σ replenishment rate of immune cells ( Althaus and De Boer, 2008 ) 10 cells · day −1 
d immune cell death rate ( Ogg et al., 1999; Casazza et al., 2001 ) 1 · 10 −2 day −1 
m maximum immune cell proliferation rate −10 −6 day −1 
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f  The R code used to produce the figures of this manuscript, as
ell as to run the computations and stochastic simulations, is pub-
icly available under https://doi.org/10.6084/m9.figshare.11536824.
1 . 
. Materials and methods 
To analyze the algebraic properties of a system of equations in-
olving cancer-immune interactions, we used the program Math-
matica ( Wolfram Research, 2011 ). To find equilibrium points in
ituations where this was not algebraically possible, we used the
ootSolve package in R ( Soetaert and Herman, 20 08; Soetaert, 20 09;
oetaert et al., 2010 ). 
Since all ordinary differential equations (ODEs) here described
re deterministic, the time course of the decline of cancer cell
umbers will always follow the same continuous trajectory given
dentical initial conditions. However, when small cancer cell num-
ers are reached, the temporal order at which the discrete events
ccur that underpin the dynamics will become important. Such
vents include the replenishment of immune cells and cancer cell
eaths. Thus, at small cell numbers, accounting for the stochastic-
ty of these events will add realism to the simulation, and help de-
ide when eradication has effectively been achieved. To this end,
e employed the Gillespie algorithm, where the interactions be-
ween cell types are explicitly simulated. Stochastic simulations
f all ODEs were run in the R language for statistical comput-
ng ( Team, 2012 ) by using the Gillespie algorithm ( Gillespie, 1977 )
ith tau leaping in the adaptivetau package ( Johnson, 2011 ). If
ot stated otherwise, simulations were run with the set of pa-
ameter values given in Table 1 . For alternative strategies to ac-
ount for the stochasticity of CISI at the temporal mesoscale see
 d’Onofrio, 2010 ). 
To model treatment, two possible procedures were considered.
irst, an increase in the ability of immune cells to detect and elim-
nate cancer cells — their killing rate or efficacy . Second, adop-
ive immune cell transfer, corresponding to the injection of im-
une cells into the system ( Rosenberg, 1991; Rosenberg et al.,
004 ). Both of these mechanisms enhance the suppression of can-
er growth by the immune system and can be applied in concert
s combination immunotherapy . The time at which the killing rate
s first enhanced, the treatment time τ k , can differ from the time
t which cancer-specific immune cells are first injected into the
ystem τ E . Also, the time period during which each of these treat-
ent approaches are administered can vary, with τ k the treat-
ent period for killing efficacy enhancement, and τ E the period
or immune cell transfer. 
We assume that treatment always consists of the administration
f either immunoactivating compounds or immune cells into the
ost system, and we denote the amount of compound delivered as
he administered dose . In the increased killing efficacy approach,
e assume that the alteration induced by the administration of
he compound is permanent, which is reflected in a change of the
illing efficacy parameter of NK or CTLs, c , or k , respectively.
he change occurs gradually over the time course of the treatment.
or example, an initial CTL killing efficacy k before treatment ini-iation will by increased by k / τ k every day, leading to a final
fficacy of k + k . 
In the immune cell transfer approach the change in immune
ell numbers is not permanent. Prior to the transfer, immune cells
re assumed to be rendered ineffective at a predefined rate (for
xample by the shedding of NKG2D ligands such as MIC-A, MIC-B
 Mellman et al., 2011 ) or alternatively, by the upregulation the lig-
nds PD-L1 or PD-L2 ( Kooi et al., 1996; Hamanishi et al., 2007 )).
nce transferred into the system, immune cell numbers will be af-
ected by already present cancer cells. Thus, immune cell numbers
ill change depending on the state of the cancer, because the can-
er exerts a suppressive effect on immune cell proliferation. Con-
ersely, cancer cell numbers will vary due to immune cell killing.
nalogously to the dosage of killing efficacy increasing compounds,
ffector cells are administered at daily doses of E / τ E cells, until
he full dose of E has been dispensed. 
. Results 
ase-model of cancer-immune system interactions 
We develop a base model of cancer-immune cell interaction.
he model follows a large body of theory that uses two-equation
eterministic ODEs to describe the interaction between cancer
umor cells and immune system cells ( Kuznetsov et al., 1994;
uznetsov and Knott, 2001; d’Onofrio, 2005; 2008; Eftimie et al.,
011; 2010; Lopez et al., 2014 ). This model aims to replicate some
asic features of cancer dynamics with a minimum of added com-
lexity. With such an approach, qualitative insights about the be-
avior of the system can be obtained by relatively simple mathe-
atical analysis. To this end, we make four fundamental assump-
ions. First, we assume the existence of immune cells, which are
ble to detect and kill tumor cells ( Parish, 2003; Smyth et al.,
001 ). These cells may eliminate microscopic tumors before they
row to endanger the organism; a process termed immunosurveil-
ance ( Burnet, 1957; 1967 ). Second, these immune cells comprise
he action of all cells that control tumor growth by antigen recog-
ition and subsequent elimination ( Eftimie et al., 2010 ), including
atural killer (NK) cells ( Khar, 1997 ) and CTLs ( Boon and van der
ruggen, 1996 ) and are termed effector cells . The process by which
he cancer cells are neutralized is called lysis ( Quesnel, 2008 ). A
ackground level of effector cells is present at all times ( de Pil-
is and Radunskaya, 2003 ). Third, we assume that tumor growth is
ell described by a logistic growth in the absence of immune cells
 Eftimie et al., 2010 ). Fourth, the interactions between tumor and
ancer cells are governed by mass-action kinetics ( Kuznetsov et al.,
994 ). 
The third assumption of logistic growth warrants special discus-
ion. The dynamics of tumor growth remain a debated issue in the
iterature. Benzekry et al. compared different theoretical growth
ynamics in lung and breast tumor data of mice ( Benzekry et al.,
014 ). They concluded that Gompertzian growth typically best pre-
icts data. Gompertzian growth dynamics are motivated by the
bservation that tumor growth prior to detection appears to be
aster than after detection ( Eftimie et al., 2010 ). This suggests that
4 V. Garcia, S. Bonhoeffer and F. Fu / Journal of Theoretical Biology 492 (2020) 110185 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Bistability of immune control of tumor growth. Increasing values of k lead to 
the emergence of a bifurcation in equilibrium tumor cell numbers. The emergence 
of the bifurcations is indicated by black, vertical dashed lines. The upper blue line 
shows the largest stable steady states and the lower dashed blue line shows the 
smallest of the steady states, while red lines show unstable steady states for a given 
k value. If bT is one, the cancer has reached carrying capacity. At bT = 0 , no cancer 
cells exist. Thus, above a threshold value k u , the cancer is cleared. The parameter 
values are m = −10 −6 , σ = 10 ( Althaus and De Boer, 2008; De Boer, 2007 ), d = 2 ×
10 −2 ( Ogg et al., 1999; Casazza et al., 2001 ), a = 0 . 514 ( de Pillis et al., 2005 ), b = 
1 . 02 × 10 −9 ( de Pillis et al., 2005 ). (For interpretation of the references to colour in 
this figure legend, the reader is referred to the web version of this article.) 
1  
t  
T  
t  
w
 
o  
a  
s  
a  
g  
i  
1  
b
 
b  
(
m  
m  
k  
k  
=  
 
k  
l  
k  
B  
i  
u l  the initial unbounded growth may be limited by the exhaustion
of growth resources or cancer cell’s mutual growth impairment.
Gompertzian growth dynamics, developed on the basis of birth
and death processes, account for this behavior, and yield a sig-
moidal type of growth curve for cancer cell numbers. However,
the Gompertz model suffers from serious drawbacks, while other
models did almost equally as well as the Gompertzian in predict-
ing data ( Benzekry et al., 2014 ). Because an upper bound of the
proliferation rate is imposed by cell division time, the Gompertz
model cannot adequately describe the dynamics of very small tu-
mors ( d’Onofrio, 2008; Eftimie et al., 2010 ). Furthermore, theoret-
ical analysis reveals that Gompertzian growth is at odds with the
immuno-surveillance hypothesis, because the immune response is
unable to eradicate cancers that grow in a Gompertzian fashion
( Eftimie et al., 2010; d’Onofrio, 2005 ). Thus, given these assess-
ments, we chose a growth model that retains a sigmoidal cancer
growth curve shape, namely logistic growth. With this, we preserve
the notion of an exhaustion of growth resources. We note how-
ever, that alternative growth models may also successfully capture
tumor growth patterns. 
Our base model differs from most models in the literature in
that it combines proliferative and suppressive effects of cancer
cells on immune cells in one single term that describes its net
effect. In this way, we can analyze how the systems behaves de-
pending on the net effect of these opposing forces. 
The equations for the base model are: 
dT 
dt 
= aT (1 − bT ) − kT E, (1)
dE 
dt 
= σ − dE + mET . (2)
Tumor or cancer cells T , grow at a maximal rate a in a logistic
fashion. The population density of the cancer cells is regulated by
the coefficient b , which acts as an inverse carrying capacity. The
cancer cells are detected and killed by effector cells E at a net rate
k ( Kuznetsov et al., 1994 ). We assume a constant supply of effector
cells at a rate σ ( Althaus and De Boer, 2008; De Boer, 2007a ), and
a death rate d per effector cell ( Wodarz, 2007 ). Effector cells can
either be stimulated to proliferate or be impaired in their growth
at a rate m , the net growth increase or decrease due to the pres-
ence of cancer cells. In other words, m can attain positive as well
as negative values. 
We proceed to analyze the possible equilibria of this system.
We start by observing that (T ∗
1 
, E ∗
1 
) = (0 , σ/d) is always a fixed
point of the ODEs above. Two further solutions for T ∗ can be rep-
resented by the quadratic formula (see Appendix A ): 
T ∗2 , 3 = 
a (m + bd) ±
√ 
s 
2 abm 
, (3)
where 
s = (a (m + bd)) 2 − 4 abm (ad − kσ ) . (4)
A closer inspection of the properties of the dynamics of (1)–
(2) reveals that all biologically relevant cases, namely those in
which T ∗
2 , 3 
> 0 , are consistent with m < 0 (see Appendix A ). This
corresponds to a net immune cell proliferation suppression by can-
cer, which can arise by various mechanisms ( Conway and Perelson,
2014; Keir et al., 2008; Mellor and Munn, 2004; Aggarwal and Pit-
tenger, 2005; Munn and Mellor, 2004; Marigo et al., 2008; Kooi
et al., 1996; Hamanishi et al., 2007 ). m < 0 is also where a bista-
bility pattern in the steady states of (1)–(2) emerges. The alterna-
tive m > 0, leads to scenarios that are at odds with well estab-
lished concepts of cancer modeling, and produce incomplete dy-
namics (see Appendix A ). In particular, they conflict with the well-
established notion of an immunological barrier ( Kuznetsov et al.,994 ); the idea that tumors have to grow above a critical threshold
o reach a large size close to carrying capacity ( Eftimie et al., 2010 ).
emporary changes in the activity of the immune system can lead
o fluctuations in tumor size which place its size above the barrier,
hich then gives rise to cancer. 
There are three possible cases of sign arrangements of the roots
f (3) under m < 0: i) both negative, ii) one positive and one neg-
tive, iii) both positive. Scenario i) has T ∗
1 
as only biologically plau-
ible solution. Only the cancer-free state exists. Case ii) signifies
 single attractive equilibrium at a non-zero tumor size. The emer-
ence of a cancerous cell suffices to ignite a replicative process that
nduces the establishment of a tumor close to carrying capacity
/ b . Thus iii), where T ∗
2 , 3 
> 0 , is the only case which admits sta-
le equilibria compatible with an existing immunological barrier. 
For T ∗
2 , 3 
> 0 to be satisfied, and while assuming that a > 0 and
 > 0 for biological reasons, we obtain the following conditions
see Appendix A ): 
 < 0 (5)
 + bd < 0 (6)
 > k l ≡ ad /σ (7)
 < k u ≡
(
ad − ( a ( m + bd ) ) 
2 
4 abm 
)
1 
σ
(8)
 k l −
(
(a (m + bd)) 2 
4 abm 
)
1 
σ
. (9)
These results reveal a bistability pattern that is mediated by the
illing efficacy k . Fig. 2 shows how the increase in the parameter k
eads to a bifurcation in the stable states of T and to bistability for
 . At k < k l the system will reside in the aforementioned case ii).
y increasing k above k l but below k u , the system will enter case
ii), and move to i) as k > k u . In line with our expectations, val-
es of k below the threshold value k represent a similar situation
V. Garcia, S. Bonhoeffer and F. Fu / Journal of Theoretical Biology 492 (2020) 110185 5 
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1  s would be expected in the absence of immune cells: unchecked
ancer growth. If k is gradually increased above k l , the tumor cells
ould have to begin replicating at increasingly large initial sizes in
rder to avoid being absorbed by the attractor at T ∗
1 
= 0 , that is,
o be suppressed by the immune system. This is where the bifur-
ation appears, and now three equilibria, of which two are stable,
ominate the dynamics. The parameter range spanned between k u 
nd k l , | k u − k l | = (a (m + bd)) 2 4 abmσ is highly dependent on the ratio of b
nd m , as well as σ . Lastly, large values of k above k u entail that
ven few effector cells are able to clear the tumor, and even large
umors are eliminated with certainty. 
At intermediate k (case iii) the base level of effector cells cru-
ially affects the dynamics. In the absence of cancer, the equilib-
ium level of effector cells is at σ / d . The appearance of cancer cells
ill induce a killing process mediated by k . High enough effector
ell levels will suppress tumor growth. In reality, the tumor might
uctuate above some threshold within which effector cells control
t, and the suppression of further T cell proliferation ( m < 0) by
he cancer will dominate over the killing. Thus, the conditions (5)–
8) mark the region of killing efficacy values that constitute an im-
unological barrier to the cancer. Increasing k values imply that
his barrier is heightened: existing effector cells improve their ca-
acity to completely eliminate the cancer. 
This analysis may serve as a model to think about how to effi-
iently combine immunotherapy approaches. These results suggest
hat one mechanism to generate biologically plausible bistability is
onsistent with situations in which the cancer’s immunosuppres-
ive effects outweigh its immunoproliferative effects ( m < 0). The
xistence of a bifurcation implies that increasing killing efficacies
ill not simply gradually diminish cancer cell numbers. Instead,
n increase above a critical value k u can terminally clear the can-
er. Equally, if k is located in the range k l < k < k u , the adoptive
ransfer of effector cells may work by perturbing cancer cell num-
ers below the unstable equilibrium point T ∗
2 
, after which it will
e absorbed into T ∗
1 
= 0 and be cleared. 
odel variations 
The here presented base-model, despite being strongly simpli-
ed, can help us intuitively understand more complex models of
ancer-immune system interactions. In the following, we demon-
trate that the basic bistability phenomenon can be replicated in
wo related, but more complex variations of the base-model. When
ossible, we also analyze whether multistability can arise, since it
s relevant to cancer dormancy , and also because it might mitigate
he effect of treatment. 
ncorporating saturation effect of tumor cells on immune response 
A natural way to extend the base-model is to include more bio-
ogically plausible assumptions about the behavior of effector cells.
ere, we retain the basic assumptions going into the base model,
ut refine the way that effector cells are reacting to the presence of
umor cells. In particular, we follow the approach by Conway et al.,
hich allows for a very general set of behaviors of effector cells to
rise and also provides estimates for the parameters ( Conway and
erelson, 2014 ). This study is set in the context of HIV, where a
reat body of theory has been devoted to the particulars of CTL
ehavior ( Wodarz, 2007 ). The equations are: 
dT 
dt 
= aT (1 − bT ) − kT E, (10)
dE 
dt 
= σ − dE + b e T 
κe + T E − d e 
T 
κ + T E. (11)d Here, the interactions governing the rate of change in tumor
ells have remained intact. Effector cell growth can now be stim-
lated at a maximum rate b e ( Davenport et al., 2004; Conway and
erelson, 2014 ). The proliferation rate saturates with the number
f tumor cells T , and is half-maximal at the Michaelis-Menten con-
tant κe ( Conway and Perelson, 2014 ). In contrast, effector cells can
e exhausted by contact with tumor cells, and die from its conse-
uences at a maximal rate d e ( Johnson et al., 2011; Conway and
erelson, 2014 ). As with proliferation, the effects of exhaustion –
ediated by κd – saturate. For typical values of these parameters
ee Table S1 in Appendix B . Models with a saturation term in dT 
dt 
ave been analyzed before ( Kirschner and Panetta, 1998 ), and have
een thoroughly discussed in for example ( Talkington et al., 2018 ).
As with the base model, T ∗
1 
= 0 is always a fixed point. The rest
f the fixed points are determined by the roots of a cubic equation
see Appendix B ). For the system of equations to generate bistabil-
ty, that is, to give rise to exactly two positive equilibria in T , the
ollowing set of conditions needs to be satisfied (see Appendix B ):
8 ABCD − 4 B 3 D + B 2 C 2 − 4 AC 3 − 27 A 2 D 2 > 0 (12)
−2 
√ 
B 2 − 3 AC 
9 A 2 
cos 
( 
1 
3 
arccos 
( 
B (2 B 2 − 9 AC) + 27 A 2 D 
6 A (B 2 − 3 AC) 
√ 
9 A 2 
B 2 − 3 AC 
) ) 
− B 
3 A 
< 0 (13) 
2 
√ 
B 2 − 3 AC 
9 A 2 
cos 
( 
1 
3 
arccos 
( 
B (2 B 2 − 9 AC) + 27 A 2 D 
6 A (3 AC − B 2 ) 
√ 
9 A 2 
B 2 − 3 AC 
) 
− 2 π
3 
)
− B 
3 A 
> 0 , (14) 
here 
 = −ab ( d − b e + d e ) , (15) 
 = ab(b e κd − d e κe − d(κd + κe )) + a (d e + d − b e ) − σ k, (16)
 = a (d e κe − b e κd ) + ad(κd + κe − bκd κe ) − σ k (κd + κe ) , (17)
 = κd κe ( ad − σ k ) . (18) 
Analogously to the base model, a closer inspection of this re-
ult reveals that biologically plausible dynamics are consistent with
 = ab ( b e − d e − d ) < 0 (see Appendix B.1 ). Interestingly, this ex-
ression is independent of κe or κd . Since a, b > 0, this im-
lies that b e < d + d e which is analogous to the situation where
 < 0 in the base model. The treatment rationale identified in the
ase model may therefore also be applicable for the extended base
odel with saturation (10)–(11) . 
In Conway et al’s work ( Conway and Perelson, 2014 ), this con-
ition is satisfied by b e < d e , which is also functionally equiva-
ent to m < 0 in our base-model: the effector cell population de-
reases due to cancer-mediated exhaustion. Importantly, the pa-
ameter choice in Conway et al. is also consistent with the emer-
ence of bistable and multistable equilibira. 
Besides bistable patterns, the system (10)–(11) can also generate
 pattern of multistability. The conditions to obtain four equilibria
n T for (10)–(11) reads: 
8 ABCD − 4 B 3 D + B 2 C 2 − 4 AC 3 − 27 A 2 D 2 > 0 (19)
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√ 
B 2 − 3 AC 
9 A 2 
cos 
(
1 
3 
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(
B (2 B 2 − 9 AC) + 27 A 2 D 
6 A (B 2 − 3 AC) √ 
9 A 2 
B 2 − 3 AC 
) ) 
− B 
3 A 
> 0 , (20)
where A, B, C and D are as in (15) . Again, a biologically plausi-
ble arrangement of equilibrium points is in agreement with A < 0.
Figure A1 shows that bistability becomes common for d e > 1 and
k > 5 · 10 −4 , with the elimination of cancer ensuing after a critical
k threshold is surpassed. 
The existence of multiple stable equilibria may be interpreted
as cancer dormancy (see Discussion ). Cancer dormancy is the phe-
nomenon of a period of non-growth of tumors. Often, this oc-
curs in small, nearly undetectable tumors residing within body tis-
sues ( Wilkie, 2013 ). Fig. A1 shows that multistability is possible
in (10)–(11) . The existence of multistability in two-equation mod-
els has been predicted and shown in other work ( d’Onofrio, 2008;
de Vladar and González, 2004; Kuznetsov et al., 1994 ). Here, we
give precise analytical conditions for its emergence under (10)–
(11) . When in a multistable regime, an increase in killing efficacy k
might not directly lead to cancer eradication if treatment is started
when the cancer is near carrying capacity 1/ b . Instead, a new mi-
croscopic steady state (MISS, ( d’Onofrio, 2008 )) might be attained
before a further increase in k leads to cancer clearance. 
Incorporating natural killer (NK) cells and tumor-specific CTL 
response 
In a next step, we incorporated a further level of complexity by
distinguishing between two types of effector cells: natural killer or
NK cells, and cytotoxic T lymphocytes or CTLs. Models that account
of the different roles between NK and CTL can be highly com-
plex ( de Pillis et al., 2005 ). To better understand where possible
bistabilities originate from, we restrict ourselves to an extension
of the base model with saturation, following an approach inspired
by de Pillis et al. (2005) and Conway and Perelson (2014) . Effector
cells are now split into NK cells N and CTLs E : 
dT 
dt 
= aT (1 − bT ) − cNT − kT E, (21)
dN 
dt 
= σ − μN + b n T 
κbn + T 
N − d n T 
κdn + T 
N, (22)
dE 
dt 
= −dE + b e T 
κbe + T 
E − d e T 
κde + T 
E + ωNT . (23)
Here, cancer cells T are killed at rates c by NK cells, and at rates
k by CTLs. The dynamics of the NK is now analogous to the dy-
namics of immune cells in (10)–(11) . We assume a constant sup-
ply of NK cells σ stemming from the host’s hematopoesis. NK cells
die naturally at a rate μ. The maximum NK proliferation rate in-
duced by the presence of cancer cells is b n , and the saturation co-
efficient is κbn . Again, exhaustion occurs at a maximum rate d n 
and the saturation in T is half-maximal at κdn . For CTLs, follow-
ing ( de Pillis et al., 2005 ), we assume that there is no constant
supply of cells. Instead, CTL growth is stimulated by the NK-cancer
cell interactions at a rate ω. This modeling approach ensures that
CTLs are activated only after the emergence of the NK immune re-
sponse ( de Pillis et al., 2005 ). Several biological mechanisms ap-
pear to exist by which NKs can stimulate CTL growth ( Pallmer and
Oxenius, 2016 ). The work of Fan et al. suggests that already acti-
vated NK cells can facilitate the priming of CTLs by means of IFN-
γ ( Fan et al., 2006 ). The proliferation and exhaustion terms are as
in the extended base model. The model (21)–(23) can generate substantially more complex
ehavior than the two previously analyzed. As in the previous
odels (1)–(2) and (10)–(11) , T ∗
1 
= 0 is always a fixed point. How-
ver, the NK-CTL model may allow for up to five other fixed points
see Appendix C ). This is because finding the steady states of (21)–
23) can be reduced to finding the roots of the rate of change of T ,
dT 
dt 
(T ) , which is a polynomial of sixth order. The five fixed points
esides T ∗
1 
= 0 , are the roots of a fifth order polynomial, for which
o general solutions exist. Thus, we cannot draw similar conclu-
ions for the existence of real fixed points as in the previous, re-
ying on analogous conditions on discriminants s > 0 or  > 0.
owever, similarly to the base model (1)–(2) , a similar condition
o m < 0 is compatible with biologically plausible arrangements of
xed point’s stabilities. The expression analogous to m < 0 is (see
ppendix C ): 
ab ( ( b e − d e − d ) ( b n − d n − μ) ) − kσω < 0 (24)
The analogy to m < 0 arises from k, σ , ω > 0, valid bounds
n most biological contexts. If tumor cells are able to exhaust NKs
nd CTLs, that is, if both ( b e − d e − d ) < 0 and ( b n − d n − μ) < 0 ,
hen the system can display biologically reasonable behavior. Note
hat unlike the previous models, this condition can be satisfied by
ther means as well, such as increasing k . Again, the condition is
ndependent of the four saturation coefficients κbe , κde , κbn , κdn . 
Due to the analytical unfeasability of the model (21)–(23) , we
esorted to numerical methods to prove the existence of basic
istability patterns (see Appendix C ) ( Soetaert and Herman, 2008;
oetaert, 2009 ). We found that the system is able to display bista-
ility similar to that found in the extended base model with satu-
ation (see Fig. A2 ). 
istability-based Strategies of Cancer Immunotherapy 
The existence of bistability patterns in simple non-spatial can-
er models as well as its variations, can be informative to the as-
essment of immunotherapeutic options and of their efficacy. Tak-
ng the base model (1)–(2) as a foundation, three intervention ap-
roaches seem apparent. First, the elimination of the exhaustive ef-
ects of cancer on the immune cells ( m < 0 → m > 0). Second, the
ncrease of the killing efficacy of effector cells above some thresh-
ld ( k < k u → k > k u ). Third, the administration of effector cells
 E → E + E). In terms of the dynamics, this represents pushing
he state of the system into the attraction basin of T = 0 . Combi-
ations of these therapy approaches have previously been explored
n simulations ( Kirschner and Panetta, 1998 ). 
In current immunotherapy, the two main available tools for
ancer cell reduction correspond to the second ( antibody ther-
py ) and third ( adoptive T cell transfer ) options ( Dougan and Dra-
off, 2009; Mellman et al., 2011 ). In antibody therapy, an in-
rease in killing efficacy is attained by disrupting cancer cells’
echanisms for impairing T cell action. This impairment oc-
urs by the acquisition of mutations in cancer cells that, for ex-
mple, lead to the expression of the PD-L1 and PD-L2 ligands
 Kooi et al., 1996; Hamanishi et al., 2007 ). These ligands are known
o bind to the PD-1 receptors on T cell surfaces, thereby downreg-
lating the activation of the T cells. Thus, a direct effect of PD-1
mmune checkpoint blockade is to halt cancer-induced T cell an-
rgy and exhaustion ( Mellman and Steinman, 2001 ). In this work
e assume that ultimately, monoclonal antibodies binding to the
igands effectively increase k by interrupting this cancer escape
echanism. Possible increases in T cell recruiting and proliferation
re neglected. In adoptive T cell transfer ( Rosenberg, 1991; Rosen-
erg et al., 2004 ), T cells are pre-programmed to kill host cells that
arry particular biochemical signatures, for example certain pep-
ides on their surface. The signatures are chosen such that they
atch characteristic features of cancer cells. Subsequently, these
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Fig. 3. Simulation runs of the base model without A) and with B) immunotherapeutic treatment. A) Cancer replication begins at T (0) = 10 2 , and the natural equilibrium 
of the effectors is at E(0) = 10 3 . The cancer grows to carrying capacity in a time frame of around 45 days. B) Combined immunotherapeutic treatment is initiated at 50 days 
after the cancer has begun to grow. It lasts for 21 days in antibody therapy, and 28 days in adoptive cell transfer. Killing efficacies are increased to k = 10 −1 , while a total 
of E = 10 5 cells are injected in a gradual fashion. Immune cells are eliminated rapidly by the powerful immune exhaustion effects exerted by the cancer cells. Parameter 
values are as in Table 1 . In particular, k = 10 −4 . 
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Fig. 4. Cancer cell numbers after combination immunotherapy after 120 days. 
Immunotherapy begins at day 50, after the cancer has grown to full size, and lasts 
for a single day. Combination immunotherapy is implemented by increasing the 
killing efficacy of the effector cells and adoptive immune transfer of effector cells. 
Darker colors indicate high cancer cell numbers, implying that the cancer persists, 
while lighter colors indicate low cancer cell numbers. Parameter values are as in 
Table 1 . 
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i  pecific T cells are grown and injected into the blood stream of
he patient ( Mellman et al., 2011 ). 
These two novel treatment methods can be combined to take
dvantage of the bistability phenomenon in cancer. We used the
ase model (1)–(2) to investigate how a combination of both ap-
roaches could be used to clear the tumor, while accounting for
he stochastic effects arising from singular cell-to-cell interactions.
tarting from an already established tumor, increasing the efficacy
f killing of effector cells will not by itself necessarily lead to the
limination of the tumor, unless very high levels of killing efficacy
an be attained. Instead, increasing the killing efficacy by two or-
ers of magnitudes will lead the system to equilibrate at tumor cell
umbers lower than the carrying capacity (see Fig. 2 ). If the treat-
ent with monoclonal antibodies has been sufficiently effective, it
ill have shifted the system into a regime with two stable equilib-
ia, out of which one is the cancer-free state. If now the system is
erturbed further with adoptive T cell transfer into the attraction
asin of the cancer-free equilibrium, the waning of the effects of
he first treatment will not lead to the reemergence of the cancer.
hus, the generation of a temporary bistability in the system can
e exploited to perturb it into a cancer-free state. 
To model the combined effects of killing efficacy increases by
D-1 specific monoclonal antibody and adoptive T cell transfer
reatments, we used stochastic version of the base cancer immune
nteraction model (1)–(2) (see Materials and Methods ). Fig. 3 shows
he time courses of the dynamics with and without treatment.
ithout treatment, a cancer that has surpassed the immunolog-
cal barrier will grow unrestricted up to levels very close to car-
ying capacity ( Fig. 3 A). The combined administration of effector
ells and killing efficacy-increasing compounds at first only gradu-
lly reduces cancer numbers ( Fig. 3 B). Daily administered effector
ells E / τ E ( Materials and Methods ) can only temporarily affect
he dynamics before they are rapidly suppressed and exhausted
y the cancer ( m < 0). When the state of the system is pushed
nto the attraction basin of the cancer-free state, cancer numbers
apidly go to zero. Further injections of effector cells become un-
ecessary, and effectors build up. 
We then investigated whether an increase in k and the admin-
stration of effector cells E work together in a synergistic or antag-
nistic fashion to remove the tumor. Fig. 4 shows the outcome of
ombination immunotherapy, initiated simultaneously for antibody
nd T cell injections. Each immunotherapeutic approach may clear
he cancer on its own. A marked frontier between cancer presence
nd clearance emerges. A lowering of killing efficacies along this
rontier will lead to insufficient pressure to clear the cancer, butan be compensated by an increase in adoptive transfer doses. The
inear shape of the frontier indicates that the two approaches do
ot mutually impair each others’ function. 
. Discussion 
In this study, we have shown that the base model can only re-
roduce biologically plausible behavior if the suppressive effects
xerted by cancer cells on immune cells dominate their prolifer-
tive effects. Under these circumstances, the base model displays
 conspicuous pattern of bistability : The cancer-immune interac-
ion dynamics gives rise to two distinct, stable states (a cancer-
ree, and a full-grown tumor state). Under bistability, the modifica-
ion of the killing efficacy can lead to a bifurcation in cancer cell
umbers, where the system may abruptly be tipped into a new,
ancer-free state. Furthermore, in situations where exhaustion pre-
ails over proliferation in immune cells, all analyzed models can
roduce bistability patterns that are biologically plausible. If this
ondition is not satisfied, the base model cannot produce biolog-
cally plausible behavior across a wide range of k values. We also
8 V. Garcia, S. Bonhoeffer and F. Fu / Journal of Theoretical Biology 492 (2020) 110185 
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nformulated more complex extensions of the base model, which can
generate multistability , a dynamic behavior that can be interpreted
as stable microscopic cancers ( d’Onofrio, 2005 ), or cancer dormancy
( Kuznetsov et al., 1994; Wilkie, 2013 ). We gave the exact conditions
under which multistability might arise in one model extension in-
spired by Conway and Perelson (2014) . We also examined how
bistability may be used for effective combination immunotherapy.
We tested a combination of two different immunotherapeutic ap-
proaches in stochastic simulations of the base model. We found
that the combination of treatment interventions is able to clear the
cancer, and that the different treatment approaches do not impair
one another. 
How both treatment approaches investigated here would work
in isolation has been studied in other work ( d’Onofrio, 2008;
Kuznetsov and Knott, 2001; Eftimie et al., 2010 ). However, it is less
apparent that they may be employed to work in concert without
mutual impairment. This is important when considering side ef-
fects of these therapies. For example, the administration of PD-1
antibodies in mice have resulted in lung inflammation and car-
diomyopathy ( Nishimura et al., 2001; 1999; Mellman et al., 2011 ).
Thus, combination immunotherapy may help minimize the risks
associated with standalone approaches. 
Another advantage of this study lies in that it specifically shows
how multistability may arise from standard assumptions about
cancer-immune system interactions (saturation terms), and in that
it gives precise conditions for its emergence. Although the first ex-
tended model with saturation (10)–(11) is not intended to admit
multiple steady states, these arise as a consequence of the basic
assumptions about interactions. 
Intermediate-sized cancers in multi-stable regimes may be in-
terpreted as cancer dormancy ( d’Onofrio, 2008; Kuznetsov et al.,
1994; de Vladar and González, 2004 ), but the model (10)–(11) does
not explicitly explain how they may escape immune control. For
immune escape to arise, additional processes must be assumed,
such as stochastic perturbations or immunoediting ( Wilkie and
Hahnfeldt, 2013a ). A discussion of how tumors might rise to large
numbers in models very similar to the base model with satura-
tion has been given in Kuznetsov et al. (1994) and by Wilkie and
Hahnfeldt (2013b) . In the Kuznetsov et al. model, a separatrix be-
tween the two main attraction basins passes close by the trivial,
cancer-free steady state. When a cancer arises and starts to repli-
cate at low numbers, it should follow a trajectory into a dormant,
stable steady state. However, stochastic fluctuations can push the
system’s state into the other attraction basin. In the Wilkie and
Hahnfeldt model, the saddle point is the dormant state itself. An-
other of the main mechanisms hypothesized to drive the transition
from dormancy to large tumors is immunoediting ( Wilkie, 2013 ):
The prolonged growth suppression of the tumor by the immune
response leads to the selection of cancer mutations that escape im-
mune pressure, effectively reducing the immune killing efficacy k
Wilkie and Hahnfeldt (2013a) . The model (10)–(11) can also offer
an intuitive explanation for this process, whereby a smaller, un-
detectable and stable equilibrium of cancer cells is maintained by
a relatively weak immune response. The further decrease of the
immune response efficacy by means of immune escape processes
leads to the establishment of a full grown tumor. This is exem-
plified by the fact that decreasing k in Fig. A1 pushes the system
into a region of parameter space where there exists a stable steady
state for the tumor at carrying capacity, that is the full grown can-
cer state. 
Most other models of cancer-immune interaction so far have
attributed the phenomenon of dormant states to the existence
of an additional compartment: quiescent cancer cells ( Page and
Uhr, 2005; Wilkie, 2013 ). These cells are assumed to replicate
at a slower rate than normal cancer cells, and can revert back
to a fast growing state by means of phenotypic switching ory acquiring further mutations ( Wilkie, 2013 ). In line with other
ork, the model (10)–(11) explains the existence of dormancy
y a specific balance of cancer cell growth and killing attained
n cancer-immune interactions, without relying on any additional
ompartments or assumptions. A notable example of how dor-
ancy can emerge from cancer-immune interactions alone is given
n Kuznetsov et al. (1994) . A third mechanism for the emergence of
ormancy has been given by Wilkie and Hahnfeldt (2013b) . In this
echanism, dormant states are represented by saddle nodes tra-
ersed by a separatrix demarcating the adjacent attractor regions
f either growth progression or tumor clearance. 
This point emphasizes a last advantage of non-spatial ODE
odels: Understanding cancer growth requires an appropriate de-
cription of cancer-immune system interactions at multiple scales
 Altrock et al., 2015 ). These scales range from cancer microenvi-
onments to large numbers of already systemic cancers. ODE mod-
ls offer useful tools to combine the behavior of both into a sin-
le framework ( Eftimie et al., 2010 ), accounting for the frequency-
ependent growth at early stages as well as the dominant im-
unosuppressive effects achieved by cancer when approaching
arrying capacity levels. 
A major caveat of the base model is that it cannot elicit an im-
une response. The elicitation of an immune response by a can-
er, with a subsequent rise in effector cells, is an important aspect
f cancer-immune system interactions. To achieve this, the base
odel would have to include a proliferation term for effectors that
akes on different values than the suppression in the T, E -plane.
he base model is thus more useful to study the aspects of how
mmunotherapy can be deployed to return the CISI system below
n immunological barrier by external perturbation. 
While simple modeling frameworks offer greater possibilities
or an in-depth understanding, this approach also has its limita-
ions. For instance, we have largely neglected stochastic attributes
f cancer-immune system interactions in our mathematical anal-
sis. These may mostly arise from the discreteness of cell-to-cell
nteractions, and are well captured by simulating the models by a
illespie algorithm ( Gillespie, 1977 ). We have addressed this short-
oming by adopting a stochastic simulation framework to imple-
ent immunotherapy. Other forms of stochasticity —for example
he random accrual of malignant mutations in cancer cells— are
lso not explictly modeled. Instead, they are assumed to be cap-
ured by model parameter values. Environmentally based fluctu-
tions ( Eftimie et al., 2010; Bose and Trimper, 2009 ), or changes
n the exerted immune pressure due to, for example, disease
 Mina et al., 2015 ), are also neglected. 
The models here analyzed do also not account for spatial struc-
ure (discussed in more detail in Araujo and McElwain, 2006;
oose et al., 2007; Chaplain, 2008 ). Spatial structure may change
he way that effector cell killing affects cancer growth, as well as
ow the presence of cancer cells may mediate immune cell pro-
iferation. In particular, we did not explore the fractional cell kill
aws as introduced by de Pillis et al. (2005) , hypothesized to ac-
ount for some of the geometrical features of tumors ( Lopez et al.,
014 ). In this approach, the total killing exerted by effectors
 ( E, T ) is governed by the de Pillis-Radunskaya-Wiseman (PRW)
aw Lopez et al. (2014) , where K(E, T ) = D (E, T ) T and D (E, T ) =
 
E λ
sT λ+ E λ . Structurally, how ( de Pillis et al., 2005 ) implement the re-
ruitment of NK cells differs only slightly from our implementation
n (21) . However, how CTLs are recruited differs in structure from
he simpler terms analyzed here in our models. With λ < 1 (ob-
ained from model fits to mouse data ( Lopez et al., 2014 )), the be-
avior of the recruiting is qualitatively similar to that studied here:
he recruiting of CTLs would then saturate with increasing cancer
ell numbers T , but continue growing with increasing effector cell
umbers E . 
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t  We thus assume that while the PRW law introduces an advan-
ageous new concept in the modeling in tumor-immune system
nteractions, our deviating from it will not yield marked qualita-
ive differences. Instead of attempting to capture tumor geometry
ehavior, the models analyzed here are rooted in the tradition of
irus dynamics —especially HIV— which assumes well-mixed cell
ypes ( Nowak and May, 20 0 0; Conway and Perelson, 2014 ). Thus,
he PRW law seems to mainly address problems arising from tu-
or geometry, while this study focuses mainly on systemic cancer
ypes —cancer types that do not manifest in single tumors only
 Eftimie et al., 2010 ). 
We have also not included the action of cytokines in our anal-
sis, which are typically accounted for with a separate, additional
quation ( Arciero et al., 2004; Kirschner and Panetta, 1998; Eftimie
t al., 2010 ). We have therefore not been able to assess the ef-
ectiveness of cytokine-based immunotherapy approaches in com-
ination with the ones studied here. Models with cytokines dis-
lay features like the persistence of large tumors, tumor dormancy,
nd tumor clearance upon immunotherapeutic treatment, as well
s oscillations between these states ( Eftimie et al., 2010; Kirschner
nd Panetta, 1998 ). Including cytokines into a more comprehensive
odeling framework would be an interesting topic for future work.
Our study has to be interpreted in the context of other models
f cancer-immune system interactions. The most comprehensive
athematical analysis of two-equation models has been put forth
y ( d’Onofrio, 20 05; 20 08 ). d’Onofrio analyzed a generalized math-
matical model in two variables —x denotes cancer and y effector
ell densities—, deriving some general results on the existence of
teady states and cancer eradication given some broad mathemat-
cal conditions on the interactions between these two cell types.
olutions were provided for the generalized model, but except for
he rate of adoptive transfers θ ( t ) (where t is time), no specific de-
endence was given on how steady states change with parameter
alue modifications. Our base model corresponds to a special case
f his general model Eqs. (1)–(2) in d’Onofrio (2008) ), with φ(x ) =
, f (x ) = a (1 − bx ) , β(x ) = 0 , q (x ) = 1 and μ(x ) = (d + | m | · x ) . As
n the models investigated in this study, d’Onofrio has observed
hat his generalized model admits a cancer-free state, and also pre-
icted that it may attain multiple stable equilibria, which he in-
erpreted as microscopic steady states (MISS) and which we in-
erpret in the context of cancer dormancy. Our own results thus
onfirm some of d’Onofrios, but go further to explore how spe-
ific cancer-immune system interaction models are concretely af-
ected by changing dynamical properties that may be tailored for
mmunotherapy. In particular, we wanted to explore some of the
roperties of CISI models that underpin the mechanisms that may
ive rise to bistability patterns (the aforementioned dominance
f immunosuppressive effects). In our models, we were therefore
ore interested in explicit analytical results, which would allow
s to study how bistability patterns depend on effector cell killing
fficacy. We also extended this approach to include how adoptive
ransfer might function under conditions with stochasticity. 
A similarly comprehensive analysis of how CISI models may
ive rise to successful adoptive immunotherapy treatments has re-
ently been put forth by Talkington et al. (2018) . Similarly to our
wn conclusions, Talkington et al. identify bistability as a ma-
or prerequisite for successful adoptive immunotherapy. Their ap-
roach is also to review a series of models of increasing complex-
ty, whereby complexity is understood to represent incorporations
f additional aspects of the immune system, such as helper cells,
nterleukin and naïve T cells into a base model. The base model is
uznetsov et al.’s early model from 1994 ( Kuznetsov et al., 1994 ),
hich, akin to our base model, assumes only two compartments:
umor and effector cells. The Kuznetsov model allows for bistabil-
ty, with a stable state of the tumor close to cancer eradication.
or all other models, Talkington et al. show that when they canive rise to bistability, adoptive immunotherapy leads to successful
utcomes in simulations. 
Future work could address whether the mechanism for bista-
ility emergence identified in this study, the dominance of im-
unosuppression by cancer over immune cell proliferation, is also
he one that gives rise to bistability in the models examined
y Talkington et al. To this end, it will be useful to embark on
 more comprehensive analysis of how mathematical models as
he ones put forth here, bring about some behavior of interest,
uch as bistability. One approach that could be taken in this di-
ection follows the axiomatic modeling framework pioneered by
omarova et al. (2003) and ( d’Onofrio, 2008; 2005 ). 
In a departure from the work of de Pillis et al. (2005) , we
ave concentrated on model features typically used in HIV model-
ng, borrowing in particular from the study of ( Conway and Perel-
on, 2014 ). The reason for this choice is that ODE-based modeling
as a long tradition in HIV and virus dynamics modeling ( Wodarz,
007; Nowak and May, 2000; Perelson and Ribeiro, 2013 ). A great
ealth of data have helped to validate interaction terms of differ-
nt cell types in mixtures, and particularly, how CTLs kill. In our
iew, these advantages can be fruitfully employed in cancer mod-
ling as well. A more inter-disciplinary integration, in particular
ith respect to CTL behavior, will benefit both fields, and allow for
he analysis of structural similarities between models that might
e harnessed for immunotherapy design. 
Our models show that biologically plausible cancer-immune
ystem interactions may be utilized to induce cancer-free states.
ncreases in the killing efficacy of immune effector cells can de-
troy the bistability pattern inherent in those models, abruptly re-
oving the basis for cancer growth. 
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ppendix A. Mathematical analysis of the base model 
Here, we describe the analysis of the system of Eqs. (1)–(2) and
ts equilibria (termed E ∗ and T ∗ in the following). To this end, we
rst solve d E/d t = 0 for E ∗, and obtain an expression in T ∗. We
hen subsitute E ∗ in dT 
∗
dt 
, and obtain a polynomial in T ∗. We aim
o find the roots of dT 
∗
dt 
(T ∗) , which are the fixed points of the sys-
em of equations. Removing the one obvious fixed point given by
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1 
, E ∗
1 
) = (0 , σ/d) , we are left with a quadratic equation in T ∗. To
obtain the other fixed points, we analyze its roots: 
dT ∗
dt 
= F (T ∗, E ∗) = abmT ∗2 − a (m + bd) T ∗ + (ad − kσ ) = 0 (25)
The solutions of (25) are given in (3) . 
With this, we can derive the exact conditions for (i) both T ∗
2 
and T ∗
3 
below zero (ii) T ∗
2 
and T ∗
3 
of different signs and (iii) both T ∗
2 
and T ∗
3 
above zero. 
We go through all cases, starting with case i). For both so-
lutions T ∗
2 , 3 
to be negative, we have two subcases ia) and ib)
of sets of conditions. Either (ia), we require that a (m + bd) < 0 ,√ 
s < | a (m + bd) | , 
√ 
s > 0 and abm > 0, or equivalently (ib),
a (m + bd) > 0 , 
√ 
s < | a (m + bd) | , 
√ 
s > 0 and abm < 0. 
We want to investigate the conditions that are equal in both
sub-cases to simplify the expressions that lead to i). Let us start by
analyzing the condition 
√ 
s < | a (m + bd) | , which is the same in
both sub-cases. This is equivalent to stating that 4 abm (ad − kσ ) >
0 . In this expression, a, b, d and σ have to be assumed to be pos-
itive for biological reasons. k , the net effector cell killing of cancer
cells can theoretically become negative, which could be the con-
sequence of cancer growth stimulation by the presence of effector
cells as reported in some recent studies ( Mellman et al., 2011 ). The
net growth stimulation from cancer cells m could theoretically be-
come negative also, since cancer cells are known to evolve mecha-
nisms that activate suppressive T regulatory cells and thus escape
effector cell action ( Mellman et al., 2011 ). This immunosuppres-
sive effect could overpower the growth stimulation of T cells in-
duced by the presence of cancer. Thus, for 4 abm (ad − kσ ) > 0 to
be valid, there exist two options: Either ad − kσ > 0 and m > 0, or
ad − kσ < 0 and m < 0. 
The other condition that appears in both sub-cases is s > 0,
which is required to obtain real solutions for T ∗
2 , 3 
. Depending on
the sign of m , this translates into different conditions for k : if
m > 0, then k > 
(
ad − (a (m + bd)) 2 / 4 abm 
)
/σ, and otherwise if
m < 0, then k < 
(
ad − (a (m + bd)) 2 / 4 abm 
)
/σ . 
These conditions on m must concord with the conditions on
abm derived before, since a, b > 0. And thus if m > 0, we are in
the same sub-case as a (m + bd) < 0 and abm > 0, whereas m < 0
must coincide with a (m + bd) > 0 and abm < 0. 
Thus, to obtain T ∗
2 , 3 
< 0 , we have two sets of conditions depen-
dent on parameter m . The first set of conditions is: 
m > 0 (26)
m + bd < 0 (27)
ad − kσ > 0 (28)
k > 
(
ad − (a (m + bd)) 
2 
4 abm 
)
1 
σ
, (29)
whereas the second set of conditions reads: 
m < 0 (30)
m + bd > 0 (31)
ad − kσ < 0 (32)
k < 
(
ad − (a (m + bd)) 
2 
4 abm 
)
1 
σ
. (33)Case ii) is of greater interest, since it entails that there will be
ne other positive solution to (1)–(2) . As in case i), there exist
wo situations in which T ∗
2 
< 0 and T ∗
3 
> 0 is attained. For these
onditions to be both true, it follows that either a (m + bd) > 0 ,
 
s > | a (m + bd) | , 
√ 
s > 0 and abm > 0, or on the other hand,
 (m + bd) < 0 , 
√ 
s > | a (m + bd) | , 
√ 
s > 0 and abm < 0. Note
hat compared to i), the inequality that compares | a (m + bd) | with
 
s has been inverted. Fortunately, again, the inequalities on
 a (m + bd) | are equivalent in both sub-cases, so we can proceed
nalyzing it. 
Following an analogous discussion as in i), it follows that for
 
s > | a (m + bd) | to be true requires either m < 0 and ad − kσ >
 , or conversely, m > 0 and ad − kσ < 0 . The conditions on m must
gain match the previous conditions on abm , since a, b > 0. With
n analogous reasoning for 
√ 
s > 0 , we ultimately obtain: 
 > 0 (34)
 + bd > 0 (35)
d − kσ < 0 ⇐⇒ k > ad/σ (36)
 > 
(
ad − (a (m + bd)) 
2 
4 abm 
)
1 
σ
, (37)
r alternatively: 
 < 0 (38)
 + bd < 0 (39)
d − kσ > 0 ⇐⇒ k < ad/σ (40)
 < 
(
ad − (a (m + bd)) 
2 
4 abm 
)
1 
σ
. (41)
The case iii) is of particular interest, since it entails that there
ould exist two non-negative cancer attractors (stable fixed points
f (1)–(2) ), which are separated by one unstable state. For both
olutions T ∗
2 , 3 
to be positive, we require that a (m + bd) > 0 , 
√ 
s <
 a (m + bd) | , √ s > 0 and abm > 0, or equivalently, a (m + bd) < 0 ,
 
s < | a (m + bd) | , 
√ 
s > 0 and abm < 0. Thus, this is identical
o case i), except for the fact that the conditions on a (m + bd) are
xactly inverted. We can therefore simply adopt the conclusions
rom the discussions of 
√ 
s < | a (m + bd) | and 
√ 
s > 0 . 
As in i), the m > 0 sub-case (one of the two possible sub-cases
n the discussion of s > 0) to obtain T ∗2 , 3 > 0 , needs to satisfy
he additional conditions a (m + bd) > 0 and abm > 0. Following
he assumptions about the values of a, b and d , this immediately
ntails that m + bd > 0 and that m > 0. The other sub-case ( m < 0)
equires a (m + bd) < 0 and abm < 0, which by analogy entails that
 + bd < 0 . 
Hence, summarizing, for all conditions for T ∗
2 , 3 
> 0 to be sat-
sfied at the same time, there exist two ways in which this can
e achieved that crucially depend on the sign of the effector cell
rowth stimulation parameter m . On the one hand, we will obtain
wo positive solutions to (1) , if: 
 > 0 (42)
 + bd > 0 (43)
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T  d − kσ > 0 (44) 
 > 
(
ad − (a (m + bd)) 
2 
4 abm 
)
1 
σ
, (45) 
r otherwise, if: 
 < 0 (46) 
 + bd < 0 (47)
d − kσ < 0 (48) 
 < 
(
ad − (a (m + bd)) 
2 
4 abm 
)
1 
σ
. (49) 
This last set of conditions with m < 0 is of particular interest.
n the one hand, m > 0 leads to biologically dissatisfactory sce-
arios: The root at T ∗
1 
= 0 is repulsive, an there exists only one
ositive attractive root T ∗
2 
> 0 . This behavior signifies a departure
rom the concept of an immunological barrier ( Eftimie et al., 2010;
uznetsov et al., 1994 ), whereby a tumor has to first surpass a
hreshold size, from which it is hindered by the immune system,
efore being able to grow to large numbers. On the other hand,
he resulting bistability pattern in the m < 0 case is reminiscent
f key features of cancer establishment and growth, which makes
hem worth studying. 
tability analysis 
To analyze the stability of the equilibria of the system of
qs. (1)–(2) , we perform a classical analysis based on the behavior
f the Jacobian of the map f : ( E, T ) → ( dE / dt, dT / dt ) at equilibrium
oints. To do this, we first interpret (1)–(2) as a map: 
dT 
dt 
= f 1 (T , E) = aT (1 − bT ) − kT E, (50)
dE 
dt 
= f 2 (T , E) = σ − dE + mET . (51)
The Jacobian, J , of the map f is thus: 
 = 
(
a (1 − bT )) − abT − kE −kT 
mE −d + mT 
)
. (52) 
For an equilibrium point to be stable, the trace of J, tr ( J ) needs
o be negative, while the determinant of J, det ( J ), needs to positive.
he trace and determinants of J must therefore satisfy: 
r(J) = d + (ab − m ) T > 0 ⇐⇒ ab > m, (53)
here T > 0 , d > 0 , 
et(J) = m + bd > 2 mbT . (54)
The second condition (54) is equivalent to m + bd 
2 mb 
> T if m > 0,
nd to m + bd 
2 mb 
< T if m < 0. If m > 0, the largest tumor fixed point is
 
∗
3 
= a (m + bd)+ 
√ 
s 
2 abm 
, from (3) . Inserting T ∗
3 
into (54) shows that the
ondition cannot be satisfied. However, T ∗
3 
does satisfy det ( J ) < 0 if
 < 0. Thus, only m < 0 scenarios can lead to the largest of the
xed points being stable. ppendix B. Mathematical analysis of the frequency dependent 
mmune response model 
To investigate the steady state solutions for the Eqs. (10)–(11) ,
e first solve for the steady state of E , which can be found analyt-
cally: 
 
∗ = σ
d − b e T κe + T + d e T κd + T 
. (55) 
Substituting E in the expression for dT / dt with Eq. (55) reduces
he finding of the steady states to a one-dimensional problem in
 
∗: 
dT ∗
dt 
= aT (1 − bT ) − kT σ
d − b e T κe + T + d e T κd + T 
= 0 . (56)
T ∗ = 0 is a trivial root of dT ∗
dt 
= 0 . After removing the trivial root
rom (56) , the remaining fixed points of the system (10)–(11) cor-
espond to the roots of: 
 (1 − bT ) − k σ
d − b e T κe + T + d e T κd + T 
= 0 . (57)
This expression can be converted into a polynomial of third or-
er in T ∗. Solving Eq. (57) is thus equivalent to the problem of
nding the roots of a cubic equation that is obtained from (57) by
liminating the denominators: 
T 3 ab ( b e − d e − d ) 
+ T 2 ( a ( d − b e + d e ) − ab(d(κe + κd ) − b e κd + d e κe )) − σ k ) 
+ T ( a (d(κe + κd ) − b e κd + d e κe ) − abdκe κd − σ k (κe + κd ) ) 
+ κd κe ( ad − σ k ) = 0 (58) 
In other words, (58) is equivalent to a cubic equation of the
orm: 
f (x ) = Ax 3 + Bx 2 + Cx + D = 0 , (59)
here T = x and 
 = ab ( b e − d e − d ) , (60) 
B = a ( d − b e + d e ) − ab ( d ( κe + κd ) − b e κd + d e κe ) ) − σ k, (61) 
 = a ( d ( κe + κd ) − b e κd + d e κe ) − abd κe κd − σ k ( κe + κd ) , (62) 
 = κd κe ( ad − σ k ) . (63) 
The cubic is analytically solvable, but tedious to write out in its
tandard representation. We thus employ a non-standard represen-
ation of these roots to better analyze the systems’ behavior and its
iological meaning. The properties of the roots of (60) are largely
ependent on the discriminant  of the cubic equation, which is
efined by: 
= 18 ABCD − 4 B 3 D + B 2 C 2 − 4 AC 3 − 27 A 2 D 2 . (64)
f  > 0 all three roots are real and distinct, if  = 0 one root is
 multiple root, and if  < 0 only one root is real, and the other
wo are complex. 
1. Two positive roots of the cubic 
With this information, we can make some assertions about the
onditions that (59) and  must satisfy for bistability to exist. Un-
er bistability, two of the three roots of (58) must be positive.
hen, together with the root T = 0 , there will be three possible
12 V. Garcia, S. Bonhoeffer and F. Fu / Journal of Theoretical Biology 492 (2020) 110185 
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positive will be dicussed next. 
Two positive roots of (58) can be attained in two ways: a)  =
0 , with both the double and the single root being positive and b)
 > 0 and only the smallest root being negative, with the other
two roots both being positive. 
The case a) is likely biologically irrelevant, since all the coeffi-
cients in (59) would have to take values to exactly satisfy  = 0 . In
case b) where  > 0 and all roots exist, we want to find conditions
under which exactly two of the three of the roots are positive. To
this end, we draw on the theory of cubic functions and on some
of its fundamental results about the nature of roots of cubic func-
tions. 
An elegant way to represent the roots of the cubic function
is by a trigonometric approach. This approach consists in mod-
ifying the standard cubic equation by means of the Tschirnhaus
transformation , where x = z − B/ 3 A, and z is the new variable. The
transformation uses the insight that the sum of the roots x N of
any n-order polynomial a n x 
n + a n −1 x n −1 · · · + a 1 x + a 0 is given by
−a n −1 /na n . Thus, the Tschirnhaus transformation corresponds to a
shift along the x-axis that relocates the cubic such that the sum
of the roots lies at the origin ( Nickalls, 2006 ). Expressing the stan-
dard cubic representation (59) in terms of the variable z leads to
the depressed cubic : 
f (z) = z 3 + pz + q, (65)
where 
p = 3 AC − B 
2 
3 A 2 
(66)
q = 2 B 
3 − 9 ABC + 27 A 2 D 
27 A 3 
. (67)
If three real solutions exist (  > 0), the roots of the depressed
equation can be expressed by the use of trigonometric functions
( Zucker, 2008; Nickalls, 2006 ). Then, the real roots of the de-
pressed cubic equation are ( Beyer and Shelby, 1975 ): 
z k = 2 
√ 
− p 
3 
cos 
( 
1 
3 
arccos 
( 
3 q 
2 p 
√ 
−3 
p 
) 
− 2 πk 
3 
) 
, k = 0 , 1 , 2 . 
(68)
This equation is only valid if the argument of the arccosine of θ =
3 q 
2 p 
√ 
−3 
p is ∈ (−1 , 1) . Interestingly, this is equivalent to demanding
that 4 p 3 + 27 q 2 ≤ 0 . This condition implies that p < 0, which is
also a necessary condition for 
√ 
− p 3 ∈ R . The solution (68) has an
elegant geometric interpretation. The roots can be represented as
the projections of the vertices of an equilateral triangle with a cir-
cle of radius 2 
√ 
− p 3 onto the x-axis. The center of the circle is lo-
cated at x N . 
Thus, what is needed to ensure that one real root is nega-
tive and two real roots are positive is to demand that the back-
transformation of the smallest root, min k z k − B/ 3 A , be smaller
than zero, and the next largest back-transformed root be positive.
Cubic function theory has produced useful results on how to find
the smallest solution min k z k ( Nickalls, 2006; Beyer and Shelby,
1975 ) as well as the position of the other roots in relation to it.
Let z 0 be interpreted as a function of p and q , that is, z 0 = C(p, q ) .
Then the three roots can be expressed in terms of C ( p, q ), namely
z 0 = C(p, q ) , z 2 = −C(p, −q ) , z 1 = −z 0 − z 2 . (69)
Furthermore, if the three roots are real, we have z 0 ≥ z 1 ≥ z 2 
( Nickalls, 2006; Beyer and Shelby, 1975 ). Thus, z is the smallest2 f the solutions, and therefore: 
in 
k 
z k = −2 
√ 
−p 
3 
cos 
( 
1 
3 
arccos 
( 
−3 q 
2 p 
√ 
−3 
p 
) ) 
. (70)
With this, the conditions to obtain one negative and two pos-
tive roots can be specified. First,  > 0 for all roots to be real-
alued, second z 2 − B/ 3 A < 0 to obtain a negative minimal root,
nd third, z 1 − B/ 3 A > 0 to ensure that the second largest root is
ositive. When replacing the values of p and q in (65) with terms
f the coefficients of the standard cubic function (59) , these condi-
ions read as follows: 
8 ABCD − 4 B 3 D + B 2 C 2 − 4 AC 3 − 27 A 2 D 2 > 0 (71)
−2 
√ 
B 2 − 3 AC 
9 A 2 
cos 
(
1 
3 
arccos 
(
B (2 B 2 − 9 AC) + 27 A 2 D 
6 A (B 2 − 3 AC) √ 
9 A 2 
B 2 − 3 AC 
) ) 
− B 
3 A 
< 0 (72)
2 
√ 
B 2 − 3 AC 
9 A 2 
cos 
( 
1 
3 
arccos 
( 
B (2 B 2 − 9 AC) + 27 A 2 D 
6 A (3 AC − B 2 ) 
√ 
9 A 2 
B 2 − 3 AC 
) 
− 2 π
3 
)
− B 
3 A 
> 0 . (73)
Expressing A, B, C and D in terms of the parameters of model
10)–(11) gives the full solutions to the conditions for bistability.
hese conditions only ensure a certain position of the roots, but
o not establish whether these roots are ordered into stable and
nstable equilibria in a biologically reasonable way. 
2. Three positive roots of the cubic 
The trigonometric interpretation of the cubic also allows us to
dentify the conditions for all roots to be positive. Applying the
ame reasoning as in the two-positive-roots case ( Appendix B.1 ),
e impose that the sum of the smallest root z k and the shift im-
lied in the Tschirnhaus transformation, x N = −B/ 3 A, is larger than
ero. In other words, we ask that the solution z k , which is located
he farthest from x N in negative-x direction should be smaller than
 N itself. In this case, all roots will come to lie on the positive part
f the x-axis, although the circle of radius 2 
√ 
− p 3 around x N might
each into negative x-values. 
The condition min 
k 
z k − B/ 3 A > 0 is thus the precise condition
or which all roots are positive. By virtue of (70) , and inserting the
alues of p and q in terms of the coefficients of the standard cubic
unction (59) , the conditions for only positive roots become: 
8 ABCD − 4 B 3 D + B 2 C 2 − 4 AC 3 − 27 A 2 D 2 > 0 (74)
−2 
√ 
B 2 − 3 AC 
9 A 2 
cos 
(
1 
3 
arccos 
(
B (2 B 2 − 9 AC) + 27 A 2 D 
6 A (B 2 − 3 AC) √ 
9 A 2 
B 2 − 3 AC 
) ) 
− B 
3 A 
> 0 . (75)
These are implicit inequalities in A, B, C and D, which in turn
epend on the parameters of model (10)–(11) by means of the re-
ation (60) . 
Expressing the coefficients A, B, C and D in terms of the param-
ters of model (10)–(11) thus gives the exact analytical conditions
nder which four non-negative fixed points to (10)–(11) exist, out
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Table 2 
Parameter values for the extended base model with saturation (10)–(11) . 
Parameter Description Value 
a maximum replication rate of unmutated tumor cells ( de Pillis et al., 2005 ) 0.514 day 
−1 
b inverse carrying capacity of tumor ( de Pillis et al., 2005 ) 1 . 02 · 10 −9 cells −1 
k killing efficiency of effector cells or CTLs ( Ganusov et al., 2011; Wick et al., 2005; Elemans et al., 2014; de Pillis et al., 2005 ) 10 −5 − 10 −3 cells −1 day −1 
σ replenishment rate of effector cells or CTLs E ( Althaus and De Boer, 2008; De Boer, 2007a ) 5 · 10 3 cells · day −1 
d effector or CTL loss rate ( Conway and Perelson, 2014 ) 2 day 
−1 
d e effector CTL immune impairment rate 10 
−3 − 10 3 day −1 
b e maximum CTL proliferation rate ( Davenport et al., 2004; Conway and Perelson, 2014 ) 1 day 
−1 
κ e saturation coefficient of effector immune growth 5 · 10 2 cells 
κd saturation coefficient of effector immune exhaustion 2.5 · 10 4 cells 
Fig. A1. Number of possible non-negative steady states of T of the model (10)–
(11) . Shown is the region of parameter space spanned by killing efficacy k and ef- 
fector cell exhaustion d e divided into regions of different non-negative fixed points 
of the model (10)–(11) . The number of roots were identified numerically by means 
of the rootSolve package in R ( Soetaert and Herman, 2008; Soetaert, 2009; Soetaert 
et al., 2010 ). Numbers indicate the number of non-negative fixed points in each pa- 
rameter region. The region that supports multistability is colored in violet. The re- 
gion that admits bistability (3 fixed points) is adjacent to the multistability region. 
The other used paramaters are as in Table 2 . 
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df which three are strictly positive. Writing this expression down
s cumbersome and hard to analyze further. However, numerical
ethods can be employed to examine which regions in parameter
pace can produce this distinctive pattern of multistability. 
3. Analyzing parameter space for existence of multistability 
We analyzed whether the conditions (71) and (74) are satisfied
or realistic parametrizations of model (10)–(11) . To this end, we
xed most parameters at biologically plausible values found in the
iterature (see Table 2 ). We then varied two of those parameters
hich are either expected to have a large impact on the system’s
ynamics, or may be less well understood. 
The standard parameter values used for the extended model
ith saturation are specified in Table 2 . 
Fig. A1 shows the regions of parameter space whose parame-
er values lead to bistability as well as multistability in the model
10)–(11) . The region that supports multistability forms a band
cross a wide range of immune cell exhaustion rate values d e . This
ndicates that when a waning of killing efficacies k occurs, the
ystem may trespass this region. A boundary is shared by a re-
ion with bistability and the parameter region that only admits aancer-free state. The mechanism for combination of immunother-
py may thus still be applicable along this boundary, which is
resent at plausible values of d e around unity. The rest of the pa-
ameter values used for the generation of this plot are within the
ange of possible values frequently used in cancer modeling. 
ppendix C. Mathematical analysis of NK-CTL model 
We follow the approach taken for both the base model and the
xtended base model with saturation and attempt to derive a func-
ion dT 
dt 
(T ) to analyze the roots of (21)–(22) , which are the fixed
oints of the system. The steady states of N and E can be found
nalytically: 
 
∗ = σ
μ − b n T κbn + T + d n 
T 
κdn + T 
, (76) 
hereas 
 
∗ = ωNT 
d − b e T κbe + T + d e 
T 
κde + T 
. (77) 
Substituting N and E in the expression for dT 
dt 
(T ) in (21)–
23) reveals that dT 
dt 
(T ) can be expressed as 
dT 
dt 
(T , 
dE 
dt 
= 0 , dN 
dt 
= 0) = P (T ) 
Q(T ) 
. (78)
Here, P (T ) = F (T ) T is a sixth-order polynomial in T . Again re-
oving the trivial solution T ∗
1 
= 0 , leaves a polynomial F ( T ) of fifth
rder. Q ( T ) is a fourth order polynomial. The roots of P ( T ) consti-
ute the remaining fixed points of the system. In general, an ana-
ytical expression for the roots for such a polynomial can only be
iven up to the fourth order. Thus, we first restrict ourselves to dis-
ussing more general properties that P ( T ) and Q ( T ) need to satisfy
n order to generate biologically plausible situations. 
For this, it is important to keep in mind that dT 
dt 
(T , dE 
dt 
=
 , dN 
dt 
= 0) has a narrow mathematical interpretation. In the three-
imensional state space spanned by T, E and N , it describes the
ehavior of dT 
dt 
along the intersection between the nullclines of E
nd N . In a three-dimensional space, this intersection is typically
 line passing through a steady state. Imagine a point with some
 -value approaching a steady state at T ∗ on the intersecting line.
or the steady state to be stable, dT 
dt 
would have to be positive as
he point, and with it T < T ∗, reaches T ∗ from below. Equally, as
he point moves past the steady state into larger values T > T ∗, dT 
dt 
ould have to grow negative. We call this a stabilizing behavior of
dT 
dt 
at the steady state. If a steady state satisfies this condition, we
all it T -stabilizing. Clearly, this behavior of dT 
dt 
around the steady
tate does not guarantee that it is stable: instability could still be
aused by other properties of the derivatives field perpendicular to
he null cline analyzed. However, it is a pre-requisite for the steady
tate to be stable. 
We begin our discussion by analyzing the simpler problem
dT 
dt 
(T ) = F (T ) T . Here, dT 
dt 
(T ) is a polynomial F ( T ) times T . The or-
er of the polynomial F ( T ) and the sign of the leading coefficient α
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Fig. A2. Bistability of cancer cell fixed points induced by immune control of tumor growth in model (21)–(23) . Panels A) to C) show the function dT / dt ( T ) (blue lines) 
for different parameter values of c. c is varied from 10 −7 (A) to 10 −3 (B) 10 0 (C). The blue points indicate the numerically found roots of dT / dt ( T ). Bistability emerges at 
c = 10 −3 . The parameter values were as specified in Table 3 . 
Table 3 
Parameter values for the extended model with saturation in NK and CTL (21)–(23) . 
Parameter Description Value 
a maximum replication rate of unmutated tumor cells ( de Pillis et al., 2005 ) 0.514 day 
−1 
b inverse carrying capacity of tumor ( de Pillis et al., 2005 ) 1 . 02 · 10 −9 cells −1 
c killing efficacy natural killer cells 10 −7 − 10 0 cells −1 day −1 
k killing efficiency of effector cells or CTLs ( Ganusov et al., 2011; Wick et al., 2005; Elemans et al., 2014 ) 10 −5 − 10 cells −1 day −1 
σ replenishment rate of effector cells or CTLs E ( Althaus and De Boer, 2008; De Boer, 2007a ) 10 − 10 3 cells · day −1 
b n proliferation rate of natural killer cells N 1.5 cells 
−1 
day 
−1 
d n exhaustion rate of natural killer cells N 1 cells 
−1 
day 
−1 
μ death rate of natural killer cells N 1 day −1 
d effector loss rate ( Conway and Perelson, 2014 ) 2 day 
−1 
d e CTL immune impairment rate ( Johnson et al., 2011; Conway and Perelson, 2014 ) 2 day 
−1 
b e maximum CTL proliferation rate ( Davenport et al., 2004; Conway and Perelson, 2014 ) 1 day 
−1 
ω growth stimulation rate of cytotoxic T lymphocytes E by natural killer cells ( de Pillis et al., 2005 ) 1 . 1 · 10 −7 cells −1 day −1 
κbe saturation coefficient of CTL immune growth 5 · 10 2 cells 
κde saturation coefficient of CTL immune exhaustion 2.5 · 10 4 cells 
κbn saturation coefficient of NK immune growth 10 
4 cells 
κdn saturation coefficient of NK immune exhaustion 10 
3 cells 
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T  of that polynomial, influences the locations of the roots of F ( T ), and
thus also of dT 
dt 
(T ) . F ( T ) also influences how the roots are arranged
into stable fixed points. 
The n th order polynomial will maximally have n real valued
roots. If n is odd, and α < 0, the smallest and largest fixed points of
F ( T ) are T -stabilizing. Conversely, if n is odd, and α > 0, the small-
est and largest fixed points of F ( T ) are unstable. If n is even, and
α < 0, the smallest fixed point of F ( T ) is unstable, while the largest
is T -stabilizing. Analogously, if n is even, and α > 0, the smallest
fixed point of F ( T ) is T -stabilizing, and the largest is unstable. 
These claims follow from the intermediate value theorem. If n
is odd, the limits of the polynomial for T → ∞ and T → −∞ will
be of opposite signs. If the leading coefficient α of the polynomial
is positive, lim 
T →−∞ 
F (T ) = −∞ , and lim 
T →∞ 
F (T ) = ∞ . To attain values
from −∞ to ∞ , F ( T ) must traverse the T -axis from negative to pos-
itive by virtue of the intermediate value theorem. Thus, the first
root must be an unstable fixed point. Since there exist an odd
number of roots, and the roots must alternate from T -stabilizing
to unstable, the last root must also be an unstable equilibrium. The
converse is true for α < 0, with both, the smallest and largest fixed
points being T -stabilizing. For even values of n , if α > 0, F ( T ) will
either be ∞ in the limit T → ± ∞ and −∞ for α < 0. Thus, fol-
lowing the same logic as with n odd, the smallest fixed point must
be T -stabilizing if α > 0, while the largest will be unstable. Con- s  ersely, if α < 0, the smallest fixed point will unstable, whereas
he largest will be T -stabilizing. 
Multiplying F ( T ) with T does not alter the position of F ( T )’s
oots. However, it will have the effect of adding a new root T = 0
o dT 
dt 
(T ) = F (T ) T , and to switch T -stabilizing into unstable (and
ice versa) fixed points if they are negative. 
With this in mind, we can now turn our attention to the full ex-
ression, dT 
dt 
(T ) = P(T ) 
Q(T ) 
. Division by Q ( T ) does not alter the position
f the roots (unless the roots of Q ( T ) are identical with the roots of
 ( T ), in which case they would cancel out). However, it can modify
he T -stabilizing properties of the roots. Roots will be T -stabilizing
f the T -derivative of dT 
dt 
(T ) is negative. Let us assume that F ( T ) has
 roots T i ( i ∈ { 1 , . . . , n } ). Then, 
d 
dT 
dT 
dt 
(T ) = F (T )(Q(T ) − T 
d 
dT 
Q(T )) + T Q(T ) d 
dT 
F (T ) 
Q 2 (T ) 
. (79)
f we evaluate this expression at a stable root of F ( T ), T i , where
d 
dT 
F (T ) < 0 , we obtain that: 
d 
dT 
dT 
dt 
(T i ) = 
T i Q(T i ) 
d 
dT 
F (T i ) 
Q 2 (T i ) 
. (80)
his entails that the of root T i > 0 (the only biologically plausible
olution) will only be stable if Q ( T ) > 0. Thus, for the roots of F ( T )i 
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 o retain their T -stabilizing properties, they will need to come to
ie in intervals of T where Q ( T ) is positive. 
Since the fixed points of (21)–(23) can be described as F ( T ) T , the
bove reasoning is valid, and we can draw conclusions about what
onditions the leading coefficient α must satisfy to ensure biolog-
cally plausible equilibria. Analyzing the structure of dT 
dt 
(T ) with
athematica ( Wolfram Research, 2011 ), reveals that the coeffi-
ient α = a 5 of the polynomial F (T ) = a 5 T 5 + a 4 T 4 + a 3 T 3 + a 2 T 2 +
 1 T 
1 + a 0 reads as follows: 
 5 = −ab ( ( b e − d e − d ) ( b n − μ − d n ) ) − kσω. (81) 
Given that the order of the polynomial F ( T ) in NK-CTL model
21)–(23) is odd, the leading coefficient a 5 of the polynomial must
e negative and the value of Q ( T ) at the largest fixed point positive
n order for F ( T ) to have a T -stabilizing largest positive fixed point.
hus, analogously to the situation in the extended base model with
aturation, the biological plausibility of the positioning of the fixed
oints is compatible with a 5 < 0. Again, a 5 expresses the balance
etween proliferative and suppressive forces acting on NK as well
s CTL cells, and is independent from the saturation coefficients.
s in the previous models, we assume that a, b, d, σ , k > 0 and it
s biologically reasonable also to assume ω > 0. Thus, interestingly,
 5 < 0 can be satisfied by increasing k σω. But if k σω is negligible,
 5 will only be negative if ( b e − d e − d ) and ( b n − μ − d n ) are both
egative or both positive. Thus, the NK-CTL model allows for more
exibility to attain biologically plausible scenarios than the two
revious models: if the balance between proliferative and suppres-
ive forces in both NK and CTLs is tipped in favor of exhaustion of
he immune cells, biologically interpretable dynamics can emerge.
his is analogous behavior to an m < 0 situation in the base model.
imilarly, if the balance is tipped towards proliferation in both cell
ypes, the arising scenarios are again biologically sound. However,
he behavior between both immune cell types must be similar to
ttain this. 
Unfortunately, the above analysis does not reveal whether bi-
r multistability can be guaranteed to arise for special combina-
ions of parameters. To show this, we must fall back to numerical
ethods. In the following, we prove that the system (21) can gen-
rate at least bistability patterns of the kind displayed by the base
odel. We only analyzed the effects of changing c , the killing effi-
acy of NKs rather than CTLs, on the system. We chose c because
K have been estimated to have faster cancer suppressing effects
han CTLs in de Pillis et al. (2005) . Fig. A2 shows the emergence of
he bistability pattern for biologically sound parameter choices in
he model (21)–(23) . The parameter values are specified in Table 3 .
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